Source: Eur Respir J 2012; 40: 814-822
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Migliori G.B., Langendam M.W., D'Ambrosio L., Centis R., Blasi F., Huitric E., Manissero D., van der Werf M.J.. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones},. Eur Respir J 2012; 40: 814-822

Member's Comments

No comment yet.

Related content which might interest you: Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Source: Eur Respir J 2010; 35: 606-613 Year: 2010 Antibiotic resistance and clinical outcomes: the CAPNETZ experience Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Increasing incidence of fluoroquinolone resistant tuberculosis in Bombay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?}, Source: Eur Respir J 2012; 40: 1051-1053 Year: 2012 Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002 Drug resistance of Mycobacterium tuberculosis to fluoroquinolones (Q) Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 TB and COVID-19 – a dangerous new combination? Source: ERS webinar 2021: TB and COVID-19 – a dangerous new combination? Year: 2021 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=229 Year: 2004 Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007 Molecular surveillance of multi-drug resistant tuberculosis in Europe Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines Source: Eur Respir J 2011; 37: 112-118 Year: 2011 Antibiotic use and misuse in the community: how to manage the problem Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Epidemiological impact of antibiotic use/misuse in the community Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=165 Year: 2004 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015